A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

National Cheng Kung University Hospital ( Site 3000), Dawan

National Cancer Center Hospital East ( Site 1002), Kashiwa

Kanagawa Cancer Center ( Site 1010), Yokohama

Medical Corporation Nahanishikai Nahanishi Clinic ( Site 1016), Naha

Saitama Cancer Center ( Site 1018), Kitaadachi-gun

National Hospital Organization Kyushu Cancer Center ( Site 1009), Fukuoka

Aichi Cancer Center Hospital ( Site 1013), Nagoya

Nagoya University Hospital ( Site 1021), Nagoya

National Hospital Organization Shikoku Cancer Center ( Site 1014), Matsuyama

National Hospital Organization Hokkaido Cancer Center ( Site 1017), Sapporo

Hokkaido University Hospital ( Site 1022), Sapporo

Hyogo Cancer Center ( Site 1005), Akashi

Hyogo College of Medicine Hospital ( Site 1019), Nishinomiya

University of Tsukuba Hospital ( Site 1020), Tsukuba

Fukushima Medical University Hospital ( Site 1012), Fukushima

Hiroshima City Hiroshima Citizens Hospital ( Site 1024), Hiroshima

Social medical corporation Hakuaikai Sagara Hospital ( Site 1008), Kagoshima

Kumamoto Shinto General Hospital ( Site 1007), Kumamoto

National Hospital Organization Osaka National Hospital ( Site 1001), Osaka

Osaka International Cancer Institute ( Site 1004), Osaka

National Cancer Center Hospital ( Site 1003), Tokyo

Juntendo University Hospital ( Site 1025), Tokyo

The Cancer Institute Hospital of JFCR ( Site 1015), Tokyo

Showa University Hospital ( Site 1023), Tokyo

Tokyo Medical University Hospital ( Site 1006), Tokyo

Seoul National University Hospital ( Site 2003), Seoul

Severance Hospital ( Site 2001), Seoul

Samsung Medical Center ( Site 2002), Seoul